357 related articles for article (PubMed ID: 14960261)
41. Calibration of pertussis toxin BRP batch 1 in a standardised CHO cell-based clustering assay.
Markey K; Douglas-Bardsley A; Hockley J; Le Tallec D; Costanzo A
Pharmeur Bio Sci Notes; 2018; 2018():112-123. PubMed ID: 30272557
[TBL] [Abstract][Full Text] [Related]
42. A collaborative study to establish the 3rd WHO International Standard for hepatitis B virus for nucleic acid amplification techniques.
Fryer JF; Heath AB; Wilkinson DE; Minor PD;
Biologicals; 2017 Mar; 46():57-63. PubMed ID: 28082100
[TBL] [Abstract][Full Text] [Related]
43. EDQM biological reference preparation for rabies vaccine (inactivated) for veterinary use.
Daas A; Bruckner L; Milne C
Pharmeur Bio Sci Notes; 2015; 2015():57-72. PubMed ID: 26830159
[TBL] [Abstract][Full Text] [Related]
44. Collaborative study for the establishment of human immunoglobulin BRP replacement batches.
Karra D; Regourd E; Costanzo A
Pharmeur Bio Sci Notes; 2018; 2018():37-61. PubMed ID: 29944115
[TBL] [Abstract][Full Text] [Related]
45. Collaborative study for establishment of a global standard for the potency assay of human anti-D immunoglobulin.
Thorpe SJ; Sands D; Fox B; Schäffner G; Yu MW; Behr-Gross ME
Pharmeuropa Bio; 2004 Jan; 2003(2):9-26. PubMed ID: 14960260
[TBL] [Abstract][Full Text] [Related]
46. Standardization: a progress report.
Saldanha J
Biologicals; 1999 Dec; 27(4):285-9. PubMed ID: 10686054
[TBL] [Abstract][Full Text] [Related]
47. Collaborative study for the establishment of Infliximab Biological Reference Preparation Batch 1.
Wadhwa M; Rigsby P; Behr-Gross ME
Pharmeur Bio Sci Notes; 2020; 2020():49-52. PubMed ID: 32459170
[TBL] [Abstract][Full Text] [Related]
48. Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines.
Xing D; Maes A; Behr-Gross ME; Costanzo A; Daas A; Buchheit KH
Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):51-63. PubMed ID: 20223190
[TBL] [Abstract][Full Text] [Related]
49. Collaborative study for the establishment of erythropoietin BRP batch 2.
Behr-Gross ME; Daas A; Bristow AF
Pharmeuropa Bio; 2004 Dec; 2004(1):23-33. PubMed ID: 15659283
[TBL] [Abstract][Full Text] [Related]
50. Quantitative real-time detection of parvovirus B19 DNA in plasma.
Koppelman MH; Cuypers HT; Emrich T; Zaaijer HL
Transfusion; 2004 Jan; 44(1):97-103. PubMed ID: 14692974
[TBL] [Abstract][Full Text] [Related]
51. World Health Organization collaborative study to calibrate the 3rd International Standard for Hepatitis C virus RNA nucleic acid amplification technology (NAT)-based assays.
Baylis SA; Heath AB;
Vox Sang; 2011 May; 100(4):409-17. PubMed ID: 21488880
[TBL] [Abstract][Full Text] [Related]
52. Establishment of the Ph. Eur. BRP for varicella vaccine batch 1.
Akkermans AM; Waeterloos G; Kemiha K; Daas A; Milne C
Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):41-54. PubMed ID: 20144451
[TBL] [Abstract][Full Text] [Related]
53. Establishment of a candidate equine influenza Florida Clade 2 strain A/eq/Richmond/1/07 horse antiserum as Ph. Eur. Biological Reference Preparation/OIE International Reference Reagent.
Paillot R; Regourd E; Behr-Gross ME
Pharmeur Bio Sci Notes; 2020; 2020():125-140. PubMed ID: 32677612
[TBL] [Abstract][Full Text] [Related]
54. A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology.
Fryer JF; Heath AB; Minor PD;
Biologicals; 2016 Jul; 44(4):242-251. PubMed ID: 27179913
[TBL] [Abstract][Full Text] [Related]
55. Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing.
Geng Y; Wu CG; Bhattacharyya SP; Tan D; Guo ZP; Yu MY
Transfusion; 2007 May; 47(5):883-9. PubMed ID: 17465954
[TBL] [Abstract][Full Text] [Related]
56. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
57. Magnetic bead technology in viral RNA and DNA extraction from plasma minipools.
Pichl L; Heitmann A; Herzog P; Oster J; Smets H; Schottstedt V
Transfusion; 2005 Jul; 45(7):1106-10. PubMed ID: 15987354
[TBL] [Abstract][Full Text] [Related]
58. Establishment of hepatitis A vaccine (inactivated, non-adsorbed) BRP batches 2 and 3.
Morgeaux S; Manniam I; Variot P; Buchheit KH; Daas A; Wierer M; Costanzo A
Pharmeur Bio Sci Notes; 2015; 2015():118-30. PubMed ID: 26830162
[TBL] [Abstract][Full Text] [Related]
59. Validation of new real-time polymerase chain reaction assays for detection of hepatitis A virus RNA and parvovirus B19 DNA.
Molenaar-de Backer MW; de Waal M; Sjerps MC; Koppelman MH
Transfusion; 2016 Feb; 56(2):440-8. PubMed ID: 26354230
[TBL] [Abstract][Full Text] [Related]
60. A collaborative study to establish the 1st WHO International Standard for Epstein-Barr virus for nucleic acid amplification techniques.
Fryer JF; Heath AB; Wilkinson DE; Minor PD;
Biologicals; 2016 Sep; 44(5):423-33. PubMed ID: 27461128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
